New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions. The data were ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

According to the company, the findings are consistent across various types of RVO, including central, branch, and hemiretinal vein occlusions. Through the 36 weeks, an 88% of the Eylea HD-treated ...

age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation ...

due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and due to choroidal neovascularization (CNV). Lucentis is contraindicated in ...

The mechanic and father of four, from the outback town of Barcaldine in central west Queensland ... vehicle fleets on the road. “(Branch retinal vein occlusion) is something that could possibly ...